Full video transcriptClick to expand
Auto-generated transcript of @michaelwardnp's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00All right, so we're talking about CJC-1295 and Ipa Morlin or Ipa Morillan and this is part two
- 0:06And so in the first video we talked about what they are and
- 0:11Kind of what they do, you know, and so in this video, we're gonna talk about how they can help you
- 0:17Your physique and your health overall and we're also gonna talk about dosing. All right, so let's talk about what they do as far as
- 0:26How they improve your physical health so they release or they cause a release of growth hormone, right?
- 0:33And so
- 0:34Whenever somebody takes human growth hormone, it's really risky and of course people who take growth hormone are gonna say no
- 0:41It's not risky, you know, but it is really risky because eventually
- 0:45What happens is you become desensitized to your own insulin, right? It causes insulin insensitivity
- 0:52And this is why you see so many bodybuilders who take growth hormone have to take insulin injections, right?
- 0:58because it creates a non insulinemic environment and
- 1:02Eventually, it's it's not good. It's not good and plus there's no there's nothing that will
- 1:09Slow down the release of growth hormone. If you inject growth hormone into your system
- 1:16That's it. It's in you got to deal with whatever happens, you know, and over time
- 1:20It grows everything anything that has a growth hormone receptor on it
- 1:24It's gonna grow. All right, and so if you are
- 1:28You know and everybody's different. It's gonna be a little different to tie it to dial somebody in with human growth hormone
- 1:35So it's gonna be tough. It's dangerous. It's risky. I would always say stay away from it
- 1:39But these peptides are different because when you inject these peptides, you're not injecting growth hormone
- 1:44You're injecting something that stimulates your body to make more growth hormone
- 1:49But there's always still something at play something called sandestatin that will pump the brakes on
- 1:55Growth hormone release if it gets too high too too far out of range for too long and so it really is
- 2:04The best of both worlds you get the safety
- 2:08But you also get the benefit that growth hormone brings with it. And so what is that?
- 2:13Well growth hormone first of all as you can imagine it stimulates the release
- 2:18I'm sorry stimulates lean muscle mass, right?
- 2:21So it's gonna stimulate your body to make more lean muscle as we age
- 2:26What is the one thing that we don't want to lose and that's our strength and our muscle mass after 40 you lose about 20?
- 2:34I think it's 20% of your muscle
- 2:38Your your muscle mass per decade, right? And it gets harder and harder to build that muscle over time. That's why these peptides work so well
- 2:47Specifically as as you age they're just going to help preserve or grow muscle whenever your body is having a very difficult time doing so
- 2:56Now what else do they do they also stimulate collagen production, right?
- 3:00This growth hormone directly stimulates collagen production and so you'll notice increase
- 3:07Thickness of your of your skin and you'll notice increased quality of your nails in your hair
- 3:13It's really fantastic. You'll see diminished fine lines and wrinkles because your body is making more collagen, right?
- 3:19And that's awesome another thing that it does is it causes weight loss around your midsection
- 3:24It decreases visceral adiposity or visceral body fat and
- 3:28Mid like our waist certain waist body fat around your midsection and so
- 3:34peptides these great these are peptides are great. This is why they are the most popular and
- 3:40And
- 3:42And let's see so let's talk about dosing. Okay, so CJC-1295
- 3:46I got a farmer stand. It's crazy
- 3:49CJC-1295
- 3:52It's dosing
- 3:54Is usually weekly or by monthly right so twice a month once a week or once every other week?
- 4:01Because of the long half life remember I mentioned in the previous video that it's got about a eight to ten day half life due to
- 4:08albumin binding via a disulfide covalent bond and so that causes it to last for a long time all right and so
- 4:18However the way that I prescribe it is I micro dose it when I combine it with CJC-1295 and I put more on and so
- 4:26you would be
- 4:28The CJC I'm sorry the Ipa morlin is 200 micrograms up to 300 micrograms
- 4:34Five days a week two hours after the last meal of the day, right?
- 4:38And you want to do that for only 12 weeks maximum 10 to 12 weeks, all right and then the
- 4:47In the CJC-1295 I do about the same so they're usually when I where I prescribe them
- 4:53They're usually compounded in their one milligram to one milligram dose
- 4:56And so I basically just prescribe the same 200 micrograms to 300 micrograms per day
- 5:02Otherwise it would be I think 65 to 75 micrograms per kilogram
- 5:10Per week and so it'd just be one dose and you would use it for one dose one one week
- 5:16Anyway, so that's that being that if you guys have any questions
- 5:21Drop me some questions if you have comments drop me some comments
- 5:24I'll be happy to answer any questions you have and if you're not following me giving me a follow
- 5:29I love talking about this stuff also. I recently created a
- 5:34TikTok subscription community you can subscribe in my profile
- 5:40And we talk about a lot of cool things up there and you have more direct access to me and we can do all kinds of cool things
- 5:47And if you just click on the subscription
- 5:50Tab you can actually see what kind of perks you get for that and yeah, let's do some big things together. All right, take care guys
CJC-1295 and ipamorelin: separating real science from peptide hype
Quick answer
CJC-1295 is a GHRH analogue with an extended half-life due to albumin binding, and ipamorelin is a selective ghrelin mimetic; both stimulate endogenous GH release through distinct mechanisms. The creator describes his personal prescribing protocol publicly, which raises concerns about the appropriateness of broadcasting specific dosing guidance to a general consumer audience on a social platform. As of 2024, FDA guidance has restricted the compounding of both compounds under 503A and 503B pharmacy exemptions, making the legal status of access to these peptides an active and unresolved regulatory issue.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For CJC-1295 and ipamorelin: separating real science from peptide hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
CJC-1295 and ipamorelin: separating real science from peptide hype should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this cjc-1295 video claims cluster
Best for searchers checking whether growth-hormone peptide claims fit evidence, access, and safety realities.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "CJC-1295 and ipamorelin: separating real science from peptide hype" from MichaelWardNP. We read the clip as a Peptide social video fact-checks claim about CJC-1295, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: CJC-1295 is a GHRH analogue with an extended half-life due to albumin binding, and ipamorelin is a selective ghrelin mimetic; both stimulate endogenous GH release through distinct mechanisms.
The reason this review is not generic is the source wording and the canonical claim label "peptides cjc 1295 and ipamorelin peptides part 2 what they do for the." In this clip, the useful excerpt is: "All right, so we're talking about CJC-1295 and Ipa Morlin or Ipa Morillan and this is part two And so in the first video we talked about what they are and Kind of what they do, you know, and so in this video, we're gonna talk about how..." That wording changes the review because it points to CJC-1295 evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. CJC-1295 decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
CJC-1295 is a GHRH analogue with an extended half-life due to albumin binding, and ipamorelin is a selective ghrelin mimetic; both stimulate endogenous GH release through distinct mechanisms.
FormBlends verdict
CJC-1295 evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- CJC-1295 is a GHRH analogue with an extended half-life due to albumin binding, and ipamorelin is a selective ghrelin mimetic; both stimulate endogenous GH release through distinct mechanisms. The creator describes his personal prescribing protocol publicly, which raises concerns about the appropriateness of broadcasting specific dosing guidance to a general consumer audience on a social platform. As of 2024, FDA guidance has restricted the compounding of both compounds under 503A and 503B pharmacy exemptions, making the legal status of access to these peptides an active and unresolved regulatory issue.
- FDA guidance issued in 2024 restricts the compounding of CJC-1295 and ipamorelin under 503A and 503B exemptions, meaning their legal availability through compounding pharmacies is actively contested in the United States.
- Somatostatin feedback is a real physiological brake on GH secretion, but it does not prevent chronically elevated IGF-1, which carries its own unresolved long-term risk profile.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- FDA guidance issued in 2024 restricts the compounding of CJC-1295 and ipamorelin under 503A and 503B exemptions, meaning their legal availability through compounding pharmacies is actively contested in the United States.
- Somatostatin feedback is a real physiological brake on GH secretion, but it does not prevent chronically elevated IGF-1, which carries its own unresolved long-term risk profile.
- Muscle loss with aging runs approximately 3 to 8 percent per decade starting around age 30, not 20 percent per decade as stated in the video (Volpi et al., 2004).
- The creator confused 'somatostatin,' an endogenous hormone, with 'Sandostatin,' a brand-name synthetic drug analogue. These are clinically distinct.
- Ipamorelin showed a cleaner hormonal profile than earlier GH secretagogues in animal studies, with minimal cortisol and prolactin elevation (Raun et al., 1998), but long-term human safety data remains limited.
- Publishing a specific dosing protocol on TikTok, framed as a personal prescribing practice, raises real concerns about off-label promotion and informed consent outside a clinical relationship.
- Anyone evaluating peptide therapy should ask a provider for baseline and follow-up IGF-1 levels and fasting glucose monitoring, regardless of what any social media video recommends.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @michaelwardnp actually say?
A nurse practitioner with 22,000-plus views told viewers that CJC-1295 and ipamorelin are safer alternatives to human growth hormone because your body's own somatostatin will "pump the brakes" if levels go too high. He also claimed these peptides stimulate lean muscle, collagen production, and reduce visceral fat. Then he gave specific dosing numbers: ipamorelin at "200 to 300 micrograms, five days a week," combined with CJC-1295 at the same dose, for a maximum of 10 to 12 weeks.
He framed the peptides as having "the best of both worlds" compared to exogenous HGH, and cited somatostatin as a built-in safety mechanism. He described this as his personal prescribing protocol, which raises immediate regulatory flags for a public TikTok video aimed at a general audience.
Does the science back this up?
The somatostatin feedback mechanism is real, but calling it a clean safety net overstates the evidence. The physiological claims about muscle, collagen, and fat loss have some support, but the data is thinner than the video implies. The dosing protocol he describes is not drawn from peer-reviewed literature.
CJC-1295 is a GHRH analogue that extends the half-life of growth hormone-releasing hormone through DAC (Drug Affinity Complex) technology, and studies like Ionescu and Frohman (2006, Growth Hormone and IGF Research) confirm its prolonged half-life of roughly 6 to 8 days. Ipamorelin is a selective ghrelin receptor agonist. A study by Raun et al. (1998, European Journal of Endocrinology) showed ipamorelin caused significant GH release in rats with minimal effect on cortisol or prolactin, which is genuinely a cleaner profile than older secretagogues. However, robust long-term human clinical trials for either compound are limited. The muscle preservation and visceral fat reduction effects are largely extrapolated from broader GH research, not peptide-specific trials in healthy aging adults.
What did they get wrong (or right)?
He got several things directionally right and at least two things meaningfully wrong. Credit where it is due: the insulin resistance concern with exogenous HGH is legitimate. Prolonged supraphysiological GH does impair insulin signaling, and this is documented in acromegaly literature (Colao et al., 2004, Journal of Clinical Endocrinology and Metabolism).
Where he stumbles: First, he calls somatostatin "sandestatin," confusing the endogenous hormone somatostatin with octreotide (Sandostatin), which is a synthetic somatostatin analogue used as a drug. These are not the same thing, and that confusion matters clinically. Second, his muscle loss statistic, "after 40 you lose about 20% of your muscle mass per decade," is imprecise. Research suggests roughly 3 to 8 percent per decade starting around age 30, accelerating after 60 (Volpi et al., 2004, Current Opinion in Clinical Nutrition and Metabolic Care). Doubling the figure is not a minor rounding error. Third, publicly posting a specific dosing protocol on TikTok, framed as "the way I prescribe it," is ethically and legally questionable regardless of his credentials.
What should you actually know?
Neither CJC-1295 nor ipamorelin is FDA-approved for general use. The FDA has placed both on its list of peptides that cannot be compounded under 503A and 503B exemptions as of 2024, citing insufficient evidence of safety and effectiveness. This is not a technicality. It means compounded versions of these peptides currently exist in a legally ambiguous space in the United States.
The somatostatin feedback loop is a real physiological check, but it does not make GH secretagogues risk-free. Potential concerns include fluid retention, carpal tunnel symptoms, increased fasting glucose, and unknown long-term effects on IGF-1 driven cell proliferation. Anyone seeing a provider about these compounds should ask specifically about IGF-1 monitoring and baseline metabolic panels. A TikTok video, even from a licensed clinician, is not a substitute for individualized evaluation.
- These peptides are not approved treatments for any disease or condition.
- The compounding status of CJC-1295 and ipamorelin is actively restricted by the FDA as of 2024.
- Somatostatin feedback is real but does not eliminate risk from chronic GH elevation.
- Anyone considering peptide therapy should discuss IGF-1 levels and glucose monitoring with their provider.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
MichaelWardNP · TikTok creator
22.3K views on this video
CJC 1295 and Ipamorelin peptides part 2! What they do for the body and dosing protocols
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about fda guidance?
FDA guidance issued in 2024 restricts the compounding of CJC-1295 and ipamorelin under 503A and 503B exemptions, meaning their legal availability through compounding pharmacies is actively contested in the United States.
What does the video say about somatostatin feedback?
Somatostatin feedback is a real physiological brake on GH secretion, but it does not prevent chronically elevated IGF-1, which carries its own unresolved long-term risk profile.
What does the video say about muscle loss with aging runs approximately 3 to 8 percent?
Muscle loss with aging runs approximately 3 to 8 percent per decade starting around age 30, not 20 percent per decade as stated in the video (Volpi et al., 2004).
What does the video say about the creator confused 'somatostatin,' an endogenous hormone, with 'sandostatin,' a?
The creator confused 'somatostatin,' an endogenous hormone, with 'Sandostatin,' a brand-name synthetic drug analogue. These are clinically distinct.
What does the video say about ipamorelin showed a cleaner hormonal profile than earlier gh secretagogues?
Ipamorelin showed a cleaner hormonal profile than earlier GH secretagogues in animal studies, with minimal cortisol and prolactin elevation (Raun et al., 1998), but long-term human safety data remains limited.
What does the video say about publishing a specific dosing protocol on tiktok, framed as a?
Publishing a specific dosing protocol on TikTok, framed as a personal prescribing practice, raises real concerns about off-label promotion and informed consent outside a clinical relationship.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by MichaelWardNP, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.